Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2751 to 2800 of 3803 results for treatment

  1. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  2. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Outcome) P: hospitalised people with COVID-19I: treatment with a combination of casirivimab and imdevimabC:• treatment in...

    Research recommendation
    Published
    21 October 2021

  3. Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)

    We have moved interventional procedures guidance 179 to become HealthTech guidance 117. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Endovenous laser treatment of the long saphenous vein (IPG52)

    We have moved interventional procedures guidance 52 to become HealthTech guidance 26. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]

    Awaiting development Reference number: GID-TA11754 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Interim methods guide for developing good practice guidance (PMG15)

    This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

  8. Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)

    NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .

    Medtech innovation briefing
    Published
    11 August 2020

  9. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

    Medtech innovation briefing
    Published
    8 April 2020

  10. What are the appropriate indications, effectiveness and safety of LDL apheresis in people with heterozygous FH?

    identify a suitable alternative treatment because LDL apheresis is generally only considered in people for whom no other...

    Research recommendation
    Published
    15 November 2019

  11. The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page . The evidence for preventing migraine is inadequate in quality. So, for preventing migraine, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    transcutaneous electrical stimulation of the supraorbital nerve for acute treatment of migraine should: Inform the clinical governance...

    Research recommendation
    Published
    7 November 2022

  12. Microwave ablation for the treatment of metastases in the liver (IPG220)

    This guidance has been updated and replaced by NICE interventional procedure guidance 406.

    Withdrawn guidance

  13. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)

    This guidance has been updated and replaced by NICE technology appraisal guidance 293.

    Withdrawn guidance

  14. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)

    Boceprevir is no longer available in the UK so this guidance has been withdrawn.

    Withdrawn guidance

  15. Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)

    NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms

    Medtech innovation briefing
    Published
    12 February 2016

  16. SecurAcath for securing cerebrospinal fluid catheters (MIB107)

    NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .

    Medtech innovation briefing
    Published
    5 June 2017

  17. Automated blood pressure monitoring in people with atrial fibrillation: Which automated blood pressure monitors are suitable for people with hypertension and atrial fibrillation?

    made the recommendation for research, see the rationale on monitoring treatment and blood pressure targets for people without...

    Research recommendation
    Published
    11 April 2022

  18. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  19. Neoadjuvant therapy:- Prospective randomised trials should be undertaken to compare preoperative (neoadjuvant) therapy with standard postoperative therapy in people with resectable pancreatic cancer.

    benefit of neoadjuvant therapy.Research is needed to compare neoadjuvant treatments (which might be chemotherapy, radiotherapy or both)...

    Research recommendation
    Published
    13 November 2018

  20. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

    HealthTech guidance
    Published
    7 August 2013
    View recommendations

    Sections for HTG315

  21. What are the long-term effects of statin therapy on sub-clinical atherosclerosis in children with FH who are treated with statin therapy?

    adverse effects of statin treatment in a population with FH, as people generally take statins for the rest of their lives once...

    Research recommendation
    Published
    15 November 2019

  22. Jejunostomy support after radical surgery:- What is the effectiveness of long-term jejunostomy support compared to intensive dietary counselling and support along with symptom management for people having radical surgery for oesophago-gastric cancer?

    patients have adjuvant treatment, however their nutritional status may negatively impact on their ability to tolerate this, meaning...

    Research recommendation
    Published
    13 November 2018

  23. In moderate- to high-severity community-acquired pneumonia does using legionella and pneumococcal urinary antigen testing in addition to other routine tests improve outcomes?

    has looked at using urinary antigen testing to target treatment. If effective, such targeted treatment could improve...

    Research recommendation
    Published
    9 June 2015

  24. Inhaled corticosteroid responsiveness:- What features predict inhaled corticosteroid responsiveness most accurately in people with COPD?

    important:- Bronchodilators and/or steroids are the main pharmacological treatments used to manage COPD. People with asthma or asthmatic...

    Research recommendation
    Published
    6 February 2019

  25. Combined bronchodilator and corticosteroid therapy for bronchiolitis:- What is the efficacy of combined bronchodilator and corticosteroid therapy?

    applicable) Why this is important:- There are no effective therapies for the treatment of bronchiolitis. One study reported that infants...

    Research recommendation
    Published
    6 October 2015

  26. Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral methotrexate for adults with early onset RA starting a new DMARD?

    important drug in the treatment of RA. Subcutaneous administration is an alternative option for people who have side effects with oral...

    Research recommendation
    Published
    11 December 2018

  27. What is the clinical and cost effectiveness of antibiotics for the management of acute diverticulitis in primary care?

    the person should be reassessed if necessary and the need for antibiotic treatment should be reviewed. The need for intravenous...

    Research recommendation
    Published
    10 February 2020

  28. Laparoscopic helium plasma coagulation for the treatment of endometriosis (IPG171)

    We have moved interventional procedures guidance 171 to become HealthTech guidance 112. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  29. Laparoscopic gastric plication for the treatment of severe obesity (IPG432)

    Interventional procedures, IPG432 - Issued: November 2012 --> We have moved interventional procedures guidance 432 to become HealthTech guidance 293. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  30. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  31. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance

  32. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  33. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)

    This guidance has been replaced by NICE technology appraisal guidance 326.

    Withdrawn guidance

  34. Cardiac resynchronisation therapy for the treatment of heart failure (TA120)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  35. Fertility: assessment and treatment for people with fertility problems (CG11)

    This guideline has been updated and replaced by NICE guideline CG156.

    Withdrawn guideline

  36. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued Reference number: GID-TA10267

    Technology appraisal guidance
    Discontinued

  37. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

    Medtech innovation briefing
    Published
    11 January 2022

  38. Sustainability

    NICE is committed to supporting the national agenda for achieving a sustainable health and care system.

  39. Living-donor lung transplantation for end-stage lung disease (HTG111)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    HealthTech guidance
    Published
    24 May 2006
    View recommendations

    Sections for HTG111

  40. Lactate level for monitoring severity of shock:- Is lactate monitoring in patients with major trauma clinically and cost effective?

    notes(if applicable) Why this is important:- In current practice, treatment for hypovolaemic shock is guided by the patient's...

    Research recommendation
    Published
    21 March 2016

  41. Further research is recommended to help address remaining clinical and cost-effectiveness uncertainties for esketamine, summarised in section 3.36 .

    assessment and decision modelling • the natural history and long-term course of treatment-resistant depression and health-related...

    Research recommendation
    Published
    6 January 2023

  42. Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)

    Interventional procedures, IPG417 - Issued: January 2012 --> We have moved interventional procedures guidance 417 to become HealthTech guidance 280. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  43. Electrocautery cutting balloon treatment for pelviureteric junction obstruction (IPG324)

    Interventional procedures, IPG324 - Issued: December 2009 --> We have moved interventional procedures guidance 324 to become HealthTech guidance 205. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  44. Implanted vagus nerve stimulation for treatment-resistant depression (IPG679)

    We have moved interventional procedures guidance 679 to become HealthTech guidance 551. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  45. What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4 alone for people with hypothyroidism whose symptoms have not responded sufficiently to T4 alone? Does DiO2 polymorphism affect the response to combination therapy with T4 and T3?

    agreed that hypothyroidism needs thyroid hormone replacement. Potential treatments are levothyroxine, usually prescribed to everyone,...

    Research recommendation
    Published
    10 February 2020

  46. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Withdrawn guidance

  47. Percutaneous interlaminar endoscopic lumbar discectomy for sciatica (HTG411)

    Evidence-based recommendations on percutaneous interlaminar endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.

    HealthTech guidance
    Published
    27 April 2016
    View recommendations

    Sections for HTG411

  48. Comprehensive assessment versus a brief assessment:- For people with a suspected common mental health disorder, what is the clinical and cost effectiveness of using a comprehensive assessment (conducted by mental health professional) versus a brief assessment (conducted by a paraprofessional)?

    remains about the accuracy and consequent identification of appropriate treatment by paraprofessionals in primary care. An assessment by...

    Research recommendation
    Published
    9 June 2015

  49. Epidurals:- What is the clinical and cost effectiveness of image-guided compared with non-image-guided epidural injections for people with acute sciatica?

    notes(if applicable) Why this is important:- Epidural injection of treatments, including corticosteroids, is commonly offered to people...

    Research recommendation
    Published
    13 February 2017

  50. Care pathway:- In the UK, what is the optimal care pathway for young people and adults with coexisting severe mental illness and substance misuse?

    important:- There is a lack of published evidence on care pathways on treatment, management and follow-up of people with coexisting...

    Research recommendation
    Published
    10 February 2017